Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Alternext  >  NOXXON Pharma NV    ALNOX   NL0012044762

NOXXON PHARMA NV

(ALNOX)
  Report
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Alternext
02/17/2020 02/18/2020 02/19/2020 02/20/2020 02/21/2020 Date
0.529(c) 0.48(c) 0.4775(c) 0.451(c) 0.45(c) Last
318 998 618 325 265 986 225 660 132 716 Volume
-6.70% -9.26% -0.52% -5.55% -0.22% Change
More quotes
Financials (EUR)
Sales 2019 -
EBIT 2019 -5,05 M
Net income 2019 -5,50 M
Debt 2019 5,06 M
Yield 2019 -
Sales 2020 1,50 M
EBIT 2020 -5,74 M
Net income 2020 -6,78 M
Debt 2020 14,4 M
Yield 2020 -
P/E ratio 2019 -
P/E ratio 2020 -
EV / Sales2019 -
EV / Sales2020 14,5x
Capitalization 7,42 M
More Financials
Company
NOXXON Pharma NV is a clinical-stage biopharmaceutical company specialized in the research and development of therapeutic products intended for the treatment of cancers. NOXXON's Spiegelmer® platform has generated a proprietary pipeline of clinical-stage product candidates including its its... 
More about the company
Latest news on NOXXON PHARMA NV
01/20NOXXON PHARMA : announces another capital increase of 0.5 million Euro through a..
PU
01/20NOXXON PHARMA : Announces Another Capital Increase of €0.5 Million Through a Pri..
BU
01/20NOXXON PHARMA NV : Admission of new securities
CO
01/17NOXXON PHARMA : N.V. - Half-yearly Report on the Liquidity Contract With Invest ..
AQ
01/16NOXXON PHARMA : Half-yearly report on the liquidity contract with Invest Securit..
PU
01/16NOXXON PHARMA N.V. : Half-yearly Report on the Liquidity Contract With Invest Se..
BU
01/14NOXXON PHARMA : announces a capital increase of 0.5 million Euro through a priva..
PU
01/14NOXXON PHARMA : Announces a Capital Increase of €0.5 Million Through a Private P..
BU
2019NOXXON PHARMA : announces first brain cancer patient reaches 10 weeks of treatme..
AQ
2019NOXXON PHARMA : Announces First Brain Cancer Patient Reaches 10 Weeks of Treatme..
BU
2019NOXXON PHARMA : Publishes Interim 2019 Results
BU
2019NOXXON PHARMA NV : Half-year results
CO
2019NOXXON PHARMA : Enrolls First Patient in the Phase 1/2 Clinical Trial Combining ..
BU
2019NOXXON PHARMA : Phase 1/2 Study with CXCL12 Inhibitor NOX-A12 and Pembrolizumab ..
PU
2019NOXXON PHARMA : presents latest clinical data from Phase 1/2 NOX-A12 / Keytruda ..
PU
More news
News in other languages on NOXXON PHARMA NV
01/21EN DIRECT DES MARCHES : LVMH, Air France KLM, PSA, Carrefour, Nicox, Logitech..
01/21BIOTECH TIME : point trésorerie pour Nicox, Gensight et Oncodesign, levée de fon..
01/21Les valeurs à suivre mardi 21 janvier 2020 à Paris -
01/21STOCK MARKET PARIS : Trump et Macron font baisser la pression
01/20NOXXON PHARMA : annonce une nouvelle augmentation de capital
More news
Sector news : Biotechnology & Medical Research - NEC
02/20Anglo American Discloses All Mine Deaths in Industry Shift--Update
DJ
02/20Anglo American Discloses All Mine Deaths in Industry Shift -- Update
DJ
02/20Anglo American Discloses All Mine Deaths in Industry Shift
DJ
02/20GlaxoSmithKline Invests $50 Million in Biotech Startup's Cell-Therapy Program
DJ
02/19Five Prime Therapeutics In License Agreement with Seattle Genetics
DJ
More sector news : Biotechnology & Medical Research - NEC
Chart NOXXON PHARMA NV
Duration : Period :
NOXXON Pharma NV Technical Analysis Chart | ALNOX | NL0012044762 | MarketScreener
Technical analysis trends NOXXON PHARMA NV
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Average target price 2,48  €
Last Close Price 0,45  €
Spread / Highest target 467%
Spread / Average Target 450%
Spread / Lowest Target 433%
EPS Revisions
Managers
NameTitle
Aram Andrew Mangasarian Chief Executive Officer
Maurizio PetitBon Chairman-Supervisory Board
Jarl Ulf Birger Jungnelius Chief Medical Officer
Hubert Birner Member-Supervisory Board
Walter Wenninger Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
NOXXON PHARMA NV-22.68%8
LONZA GROUP19.03%31 732
IQVIA HOLDINGS INC.5.77%31 649
SEATTLE GENETICS, INC.2.40%20 383
CELLTRION, INC.--.--%19 812
INCYTE CORPORATION-5.21%17 943